Nuvation Bio (NUVB) Cash from Investing Activities (2020 - 2026)

Nuvation Bio (NUVB) has reported Cash from Investing Activities for 7 consecutive years, with -$43.6 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Cash from Investing Activities fell 180.54% year-over-year to -$43.6 million; the TTM figure through Mar 2026 stood at $1.7 million (down 98.99% YoY), while the FY2025 annual figure was $99.5 million, down 18.89% from the prior year.
• Cash from Investing Activities fell to -$43.6 million in Q1 2026 per NUVB's latest filing, from $87.1 million in the prior quarter.
• Across five years, Cash from Investing Activities topped out at $106.4 million in Q3 2022 and bottomed at -$96.6 million in Q3 2025.
• Historically, Cash from Investing Activities has averaged $14.8 million across 5 years, with a median of $29.1 million in 2024.
• Annual changes were most pronounced in 2023 — Cash from Investing Activities tumbled 836.7% — and 2025, when it soared 618.4%.
• Nuvation Bio's Cash from Investing Activities stood at -$21.8 million in 2022, then jumped by 251.92% to $33.2 million in 2023, then jumped by 56.11% to $51.8 million in 2024, then soared by 68.2% to $87.1 million in 2025, then tumbled by 150.11% to -$43.6 million in 2026.
• Business Quant data shows NUVB's Cash from Investing Activities at -$43.6 million in Q1 2026, $87.1 million in Q4 2025, and -$96.6 million in Q3 2025.